Share on StockTwits

Achillion Pharmaceuticals (NASDAQ:ACHN) Director Gary E. Frashier sold 5,000 shares of Achillion Pharmaceuticals stock on the open market in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $8.00, for a total value of $40,000.00. Following the sale, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $40,000. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

A number of analysts have recently weighed in on ACHN shares. Analysts at Maxim Group reiterated a “buy” rating on shares of Achillion Pharmaceuticals in a research note on Friday. Separately, analysts at FBR Capital Markets initiated coverage on shares of Achillion Pharmaceuticals in a research note on Friday. They set an “outperform” rating and a $12.00 price target on the stock. Finally, analysts at Piper Jaffray upgraded shares of Achillion Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research note on Monday, August 11th. They now have a $10.00 price target on the stock, up previously from $5.00. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $7.80.

Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) traded up 9.60% during mid-day trading on Friday, hitting $9.25. The stock had a trading volume of 21,933,368 shares. Achillion Pharmaceuticals has a one year low of $2.26 and a one year high of $9.94. The stock’s 50-day moving average is $7.3 and its 200-day moving average is $4.58. The company’s market cap is $904.5 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Thursday, August 7th. The company reported ($0.16) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.18) by $0.02. On average, analysts predict that Achillion Pharmaceuticals will post $-0.73 EPS for the current fiscal year.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.